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By and large, gene expression levels in diploid organisms
reflect the combined transcription of both copies, or alleles,
of that gene. Notable exceptions include genes on the X
chromosome and imprinted genes. The presence of genes
in only one copy or in more than two copies can have ma-
jor effects on the development and fitness of an organism.
Many examples of these gene dosage effects can be found in
 
model genetic organisms such as 
 
Drosophila
 
 and in inherited
disorders in humans. Examples include the well-known ef-
fects of trisomy and contiguous gene deletion syndromes. It
is now a well-established fact that inheritance of one mutant
copy of a tumor suppressor gene (TSG) may predispose an
individual to cancer because of loss of the remaining wild-
type allele in somatic cells, resulting in cells completely de-
void of the TSG product (for a review, see reference 1).
However, more recent data suggest that some genes, when
expressed at half normal levels, i.e., from only one func-
tional allele, cannot fully suppress tumor growth (2, 3). In
this issue, Rego et al. (4) report data showing that promy-
elocytic leukemia protein (
 
PML) 
 
gene dosage has a major
impact on the development of acute promyelocytic leuke-
mia (APL) induced by transgenic overexpression of the
 
PML-retinoic acid receptor 
 
a 
 
(RAR
 
a
 
) fusion oncoprotein.
The authors went on to show that heterozygous 
 
PML
 
 loss
controls the sensitivity of PML-RAR
 
a
 
–positive cells to ap-
optosis induction and differentiation by vitamin D3. In an
accompanying report in this issue by Kogan et al., a role for
apoptosis suppression in APL progression was also suggested
by experiments showing that a 
 
Bcl2
 
 transgene dramatically
synergized with a PML-RAR
 
a
 
 transgene in tumor induc-
tion (5). Together, these results show that APL develop-
ment involves overcoming apoptosis sensitivity, which
likely occurs in part due to loss of one normal copy of the
 
PML
 
 gene. Indeed, another class of TSGs may exist, per-
haps with very context-specific effects, which are haploin-
sufficient for tumor suppression and will be found mutated
in only one copy in cancer cells. This idea has important
basic science and clinical implications.
It should come as no surprise that a complex process,
such as multistep cancer development, would not be sub-
ject to gene dosage effects. Indeed, literature on cancer
genes is full of evidence that gene dosage plays a determin-
ing role in whether a given mutation can exert its onco-
genic effect. Many oncogenes become amplified in cancer
 
cells (6). Examples include 
 
NMYC
 
 amplification in neuro-
blastoma and 
 
HER2/NEU 
 
amplification in breast carci-
noma. Indeed, 
 
RAS
 
 genes activated by point mutation are
also usually overexpressed in cancer cells, sometimes as a
result of gene amplification (7, 8). Substitution of only one
 
Ras
 
 allele with a point-mutated, activated version using ho-
mologous recombination does not by itself cause morpho-
logical transformation of fibroblasts (9). Instead, this sub-
stitution increases the likelihood of morphological
transformation after some other mechanism has increased
expression levels from the mutated allele. Moreover, cancer
cytogenetic studies, and more recently comparative ge-
nome hybridization studies, show that cancer cells have
major, recurrent chromosome gains and losses that may be
selected for because they result in too little or too much
expression of whole sets of genes (10, 11). Identifying such
genes is likely to be very difficult. Classical TSGs can be
identified because both alleles are inactivated in cancer cells
and often cause hereditary cancer predisposition syndromes
when inherited in mutant forms. The prototypical TSG is
the retinoblastoma gene, 
 
RB1
 
 (for a review, see reference
12). Patients who inherit one inactive copy of the 
 
RB1
 
gene are predisposed to develop multiple retinoblastomas
after somatic inactivation of the wild-type allele. Inactiva-
tion of the wild-type allele can occur by loss of the whole
chromosome carrying the wild-type allele, mitotic recom-
bination, large or small chromosomal deletions, or point
mutation of the wild-type allele (Fig. 1). Most of these
events result in loss of heterozygosity (LOH) for polymor-
phic markers within and near the affected TSG. Therefore,
consistent LOH is used as a tool for narrowing the region
of interest when positionally cloning new TSGs. But such
an approach will of course exclude identification of genes
that require two functional copies to adequately suppress
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tumor cell growth and thus will have only one inactivated
allele in tumors.
Although dominant, activated protooncogenes can be
identified in many ways, creation of one class of protoon-
cogenes consistently results in monoallelic loss of two
genes: fusion genes created by chromosomal translocation
or inversion. Most notably in leukemia, but also in other
tumor types, oncogenes may be created by the fusion of
two genes to create a chimeric fusion oncoprotein (for re-
views, see references 13 and 14). It has been long appreci-
ated that such an event also inactivates one copy of each
gene involved in the translocation or inversion that creates
the fusion oncoprotein. Does the loss of one normal copy
of a gene involved in such a translocation contribute to
leukemia development? This is the question Rego et al. (4)
set out to answer in their study.
APL is closely associated with expression of a chimeric
fusion oncoprotein, PML-RAR
 
a
 
, composed of PML and
RAR
 
a 
 
protein sequences (for a review, see reference 15).
Alternative RAR
 
a
 
 fusions are present in 
 
,
 
1.5% of APL
(16). In the vast majority of APL patients, a balanced recip-
rocal translocation, t(15;17)(q22;q11.2), results in the gen-
eration of the 
 
PML-RAR
 
a
 
 fusion oncogene (16). This
translocation not only creates a 
 
PML-RAR
 
a
 
 fusion, it also
creates a 
 
RAR
 
a
 
-PML fusion gene, and causes haploinsuffi-
ciency for both 
 
PML
 
 and 
 
RAR
 
a
 
. These additional changes
could play important roles in leukemia pathogenesis.
A 
 
PML-RAR
 
a
 
 transgene can initiate leukemia with pro-
myelocytic features, indicating that the additional changes
wrought by the translocation are not essential for leukemia
formation (17–19). Nevertheless, additional changes may
have a permissive role, promoting the transition from a
 
PML-RAR
 
a
 
 initiated disturbance of myelopoiesis to acute
leukemia. The RAR
 
a
 
-PML fusion is not expressed in
 
z
 
30% of APL (16), and a 
 
RAR
 
a
 
-
 
PML
 
 transgene did not
initiate leukemia in mice (20). Nevertheless, this reciprocal
fusion did increase the penetrance of leukemia in mice ex-
pressing 
 
PML-RAR
 
a
 
 (20). Similarly, 
 
Pml
 
2
 
/
 
2
 
 mice do not
have an increased incidence of spontaneous malignancies
(21), but Rego et al. have now demonstrated that reduc-
tion in 
 
Pml
 
 gene dosage cooperates with a 
 
PML-RAR
 
a
 
transgene to decrease latency and increase the penetrance
of acute leukemia (4). These findings make apparent that
the combination of genetic changes effected by chromo-
somal translocations may be critical to the ability of these
events to cause malignancies. Recent efforts to create chro-
mosomal translocations in mice, including reciprocal fusion
genes, haploinsufficiency for both partners, and expression
under native promoter elements (22), may provide addi-
tional insights into the effects of such aberrations.
The results of Rego et al. definitively demonstrate that
abrogation of PML function promotes myeloid leukemo-
genesis (4). Their study goes on to show that loss of PML
likely contributes to leukemogenesis by enhancing survival
of immature myeloid cells and by making these cells resis-
tant to differentiating stimuli. Furthermore, these results
strongly suggest that haploinsufficiency for 
 
PML
 
 contrib-
utes to leukemia formation in humans. In the mice, as in
humans, PML function was impaired through two distinct
mechanisms: functional impairment by PML-RAR
 
a
 
 and
reduction in 
 
Pml
 
 gene dosage. Decreasing PML function
by increasing PML-RAR
 
a
 
 expression and/or by reducing
the number of intact 
 
Pml
 
 genes resulted in decreased sur-
vival and increased leukemia incidence in 
 
PML-RAR
 
a
 
transgenic mice. Given this dose effect, it appears likely that
haploinsufficiency for 
 
PML
 
 does contribute to human
APL. Additional evidence in support of a role for 
 
PML
 
haploinsufficiency in leukemogenesis comes from previous
work from the Pandolfi laboratory showing that loss of one
allele of 
 
Pml
 
 could combine with PML-RAR
 
a
 
 expression
to suppress cell death (23). One formal caveat to the hy-
pothesis that 
 
PML
 
 haploinsufficiency is relevant to human
APL must be noted. Although it is clear that the levels of
PML-RAR
 
a
 
 expressed in the mice (even those homozy-
gous for the transgene) do not phenocopy the effects of ho-
mozygous 
 
Pml
 
 gene loss, it remains possible that the levels
of PML-RAR
 
a
 
 expressed as a result of the t(15;17) trans-
location in human cells are sufficient to completely abolish
PML function.
 
PML
 
 has appropriately been added to the list of genes
with tumor suppressor activity. As a tumor suppressor,
 
PML
 
 has several interesting features. First, loss of 
 
Pml
 
 in
mice does not itself initiate malignancies. Second, in hu-
man leukemia the decrease in PML function is brought
about by dominant-negative activity of a gene fusion facili-
tated by accompanying haploinsufficiency. Additional as-
pects of PML’s ability to inhibit tumor formation remain to
be explored. Many tumor suppressors only make them-
selves apparent upon homozygous gene inactivation (as
with 
 
RB1
 
) or upon creation of a dominant-negative allele
that is sufficiently strong as to render cells functionally null
(as with many 
 
TP53
 
 mutations). Haploinsufficiency pro-
Figure 1. Mechanisms for loss of tumor suppression activity. A normal
cell with one mutated TSG allele (TSG2) on the dark chromosome and
one wild-type allele (TSG1) on the white chromosome is shown in the
oval. Classical TSGs are somatically inactivated by one of the mechanisms
shown in the bottom box, resulting in tumor formation. A class of TSG
genes, such as PML, may be unable to fully suppress tumor cell growth in
the presence of a factor, shown here as protein X, which can partially in-
hibit TSG protein function. In APL, factor X is the PML-RARa fusion
oncoprotein itself. In this model, the order of events could be switched,
they could occur simultaneously, and the inhibition of TSG function
could be more indirect than shown here. 
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moted leukemic transformation in 
 
PML-RAR
 
a
 
 transgenic
mice. However, the authors do not present data on
whether or not the remaining 
 
Pml
 
 allele is expressed in the
leukemic cells. It is possible that the effect of haploinsuffi-
ciency on leukemia formation was due primarily to reduc-
tion to homozygous gene loss or to transcriptional silencing
in somatic cells. The demonstration that normal PML is ac-
tually expressed in leukemias that arise in 
 
PML-RAR
 
a
 
/
 
Pml
 
1
 
/
 
2
 
 mice would provide additional evidence that 
 
Pml
 
 is
not a typical TSG. Demonstration of PML tumor suppres-
sor activity has been limited to few cell types, including
myeloid leukemia, lymphoma, fibrohistiocytoma, and skin
(21, 24). As with other TSGs, the tissue specificity of 
 
Pml
 
remains an area of opportunity for novel investigations.
The suggestion of Rego et al. (4) that this specificity is re-
lated to the relative importance of proliferation and apop-
tosis in tumor expansion appears a good point of departure
for future work. Indeed, experiments reported by Kogan et
al. in this issue demonstrate that inhibition of apoptosis by
expression of the 
 
Bcl2
 
 oncogene can cooperate with the
 
PML-RAR
 
a
 
 transgene in APL generation (5). Interest-
ingly, the authors also presents data suggesting that, like re-
duction of the dose of 
 
Pml
 
, expression of 
 
Bcl2
 
 at high levels
can partially block differentiation. A role in blocking differ-
entiation is a relatively understudied activity of the 
 
BCL2
 
protooncogene. Whether this differentiation block also de-
pends on the well-known role of Bcl2 in mitochondrial
permeability is unknown.
 
PML
 
 can be placed, at least presumptively, into a cate-
gory of TSGs in which haploinsufficiency is sufficient to
contribute to tumorigenesis. Other genes, which may also
share this characteristic, are 
 
P27KIP1
 
 and 
 
AML1/RUNX1
 
(2, 3). The 
 
AML1
 
, or 
 
RUNX1
 
, gene encodes a sequence-
specific DNA binding transcriptional repressor protein (for
a review, see reference 25). Homozygous loss of 
 
AmL1
 
 in
knockout mice causes embryonic lethality due to an im-
pairment in definitive hematopoiesis (26). In people, inher-
itance of one mutant copy of the 
 
AML1
 
 gene causes a
thrombocytopenia with predisposition to acute myeloid
leukemia (AML) development (3). Interestingly, AML
which develop in these patients does not show loss of the
 
AML1
 
1
 
 allele, suggesting that this gene may predispose
cells to leukemic transformation without biallelic inactiva-
tion. 
 
AML1
 
 is a partner in several translocations commonly
found in human leukemia and so, like 
 
PML
 
, is reduced to
hemizygosity by the same events that fuse it to other genes
to generate the fusion oncoprotein. This family of fusion
oncoproteins may also cooperate with loss of one copy of
the 
 
AML1
 
 gene, and in fact biochemical and genetic evi-
dence suggests that AML1-ETO antagonizes AML1 func-
tion (27). The 
 
P27KIP1
 
 gene encodes a cyclin-dependent
kinase inhibitor that maps to human chromosome 12p12.
Deletions in this region are common in human B cell acute
lymphoblastic leukemia (ALL) and consistently include the
 
P27KIP1
 
 gene. However, the wild-type allele is not mu-
tated in these 
 
ALL
 
, suggesting that 
 
P27KIP1
 
 is haploinsuf-
ficient for ALL tumor suppression (2). Similar results were
obtained with mice heterozygous for the 
 
p27kip1
 
 gene
(28). Mice heterozygous for 
 
p27kip1
 
 were found to be pre-
disposed to gamma irradiation or chemically induced tu-
mors. Furthermore, the tumors that developed in these
heterozygous animals showed neither mutation of nor si-
lencing of the wild-type allele.
Are haploinsufficient TSGs commonly involved in the
development of human cancer? Some well-known, recur-
rent chromosomal deletions or monosomies may actually be
selected for due to loss of a haploinsufficient TSG. Only
one copy of the TSG would be lost in these cases, hinder-
ing attempts to identify the gene(s) involved. Indeed, al-
though biallelic deletions can be observed in solid cancer
with loss of 
 
RB1
 
 and other TSGs, such biallelic deletion has
not been reported in 5q- or monosomy 7 syndrome, com-
mon forms of myeloid leukemia. Perhaps this is because a
haploinsufficient TSG resides in these regions. Such a situa-
tion would necessitate a new strategy for finding these
TSGs. One might choose tumors which share clinical fea-
tures with 5q- or Mo7 syndrome, but which lack large de-
letions in these regions, hoping to identify monoallelic in-
activation of a gene. It may also be possible to test for the
presence of haploinsufficient TSG in the syntenic regions of
the mouse genome by generating large chromosomal dele-
tions in mouse embryonic stem (ES) cells and looking for
cancer in mice subsequently generated from these cells.
Several methods exist for generating large deletions in spe-
cific chromosomal regions in mouse ES cells (29, 30). Such
deletions could be expected to contribute to tumor forma-
tion without loss of genetic material or gene mutations on
the wild-type chromosome. As Rego et al. show (4), the
effects of this sort of TSG loss may be very context specific
and so such models may have to accommodate the right tis-
sue, target cell, and presence of the right additional genetic
events. In the case of PML, its heterozygous inactivation
may contribute to APL induced by PML-RAR
 
a
 
 specifi-
cally because the fusion oncoprotein also partially blocks
PML function. However, one could imagine less direct rea-
sons for context-specific effects of heterozygous TSG inac-
tivation. Partial suppression of TSG protein function could
be mediated by intrinsic factors such as the expression of
viral genes, specific oncogene mutations, or loss of other
TSGs. Alternatively, extrinsic factors such as growth factors,
cytokines, or the presence of specific cell types could com-
promise TSG protein function. For haploinsufficient TSGs,
these other factors represent a new way of thinking about
loss of tumor suppression activity quite different from the
traditional loss of the wild-type tumor suppressor allele in a
heterozygous cell (Fig. 1). Understanding why these con-
text-specific effects occur will be very important because
they could suggest very specific, new routes for therapeutic
intervention. Related to this idea, if some TSGs are insuffi-
cient to fully suppress tumor cell growth in one copy and
one wild-type copy of the gene remains in tumor cells, it
may be possible to boost its expression or the activity of its
protein product to achieve a therapeutic effect.
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